RxDoctor Payments DataLook up a doctor →

Heather Blanchette, APRN

Nurse Practitioner · Largo, FLNPI 1316936347

Payments from drug & device makers

$19,728in general payments, 2019–2025

Across 669 payments — averaging $29.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • AstraZeneca$2K
  • Johnson & Johnson$1K
  • Lilly USA, LLC$840
  • Incyte Corporation$774
  • Daiichi Sankyo Inc.$723
  • plus $11K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis70$3,013
AstraZeneca(2 entities)59$1,969
Johnson & Johnson(2 entities)37$1,091
Lilly USA, LLC20$840
Incyte Corporation29$774
Daiichi Sankyo Inc.24$723
Sanofi27$707
Merck30$688
Rigel Pharmaceuticals, Inc.9$582
Pfizer28$578
GSK16$574
Bristol Myers Squibb32$527
Gilead(2 entities)24$515
Ipsen Biopharmaceuticals, Inc13$487
AbbVie16$457
E.r. Squibb & Sons, L.L.C.14$370
Karyopharm Therapeutics Inc.6$326
Takeda Pharmaceuticals U.S.A., Inc.13$322
Blueprint Medicines Corporation6$299
Bayer12$254
Regeneron Healthcare Solutions, Inc.9$250
Eisai Inc.6$238
Jazz Pharmaceuticals Inc.10$236
Seagen Inc.15$232
Pharmacyclics LLC, An Abbvie Company5$210
Myriad Genetic Laboratories, Inc.5$194
Array Biopharma Inc9$169
Adaptive Biotechnologies Corporation2$159
Stryker1$149
Astellas Pharma US Inc7$141
CSL Behring8$137
AVEO Pharmaceuticals, Inc.7$133
Astellas Pharma Global Development1$125
Dendreon Pharmaceuticals LLC4$125
Pharmacosmos Therapeutics Inc.6$125
Sanofi US Services Inc.1$121
Sobi, Inc7$119
Exelixis Inc.6$113
Amgen5$108
CTI Biopharma Corp.2$94
Genentech USA, Inc.5$89
Pharmaessentia USA Corporation4$88
Janssen Scientific Affairs, LLC1$84
Kyowa Kirin, Inc.3$81
Puma Biotechnology, Inc.4$76
Stemline Therapeutics Inc.3$75
Morphosys, US Inc.1$69
Deciphera Pharmaceuticals Inc.4$68
Taiho Oncology, Inc.4$67
Beigene USA, Inc.4$67
EMD Serono, Inc.3$64
Alnylam Pharmaceuticals Inc.3$56
Tersera Therapeutics LLC2$47
Myovant Sciences Inc.3$45
Boehringer Ingelheim2$43
Syndax Pharmaceuticals, Inc.2$41
Servier Pharmaceuticals LLC2$41
Tactile Systems Technology Inc1$40
Mirati Therapeutics, Inc.2$40
Legend Biotech USA Inc.2$39

How this compares

$19,728 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida →

Medicare billing

Part B allowed, 2024
$20,608
Medicare patients
32
Services billed
4,405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nurse practitioner in Largo

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →